March 22nd 2023
BRIO-I is a double-masked, randomized, multi-center, safety and efficacy study that enrolled emmetropic phakic and pseudophakic presbyopic subjects.
December 31st 2022
Presbyopia-correcting IOL receives high marksAugust 26th 2022
The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.
New advancements in IOL technology is exciting for presbyopia treatmentMay 11th 2022
Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.
Visus Therapeutics, Zhaoke Ophthalmology announce licensing agreement to commercialize presbyopia treatment overseasMay 11th 2022
The companies will collaborate to commercialize therapeutic option in Greater China, South Korea and Select Southeast Asian Markets for the treatment of presbyopia, expanding access to long-acting, presbyopia-correcting eye drops for approximately 600 million patients.
CSF-1 Phase 2B clinical trials for presbyopia met primary and secondary endpointsApril 25th 2022
In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.
Orasis phase 2b data for CSF-1 presented at ASCRSApril 23rd 2022
For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.
Emerging medical and surgical presbyopic treatmentsApril 18th 2022
Ophthalmologists have several options at their disposal for the treatment of presbyopia, according to Elizabeth Yeu, MD, a partner at Virginia Eye Consultants and an assistant professor at Eastern Virginia Med¬ical School in Norfolk. Speaking recently at the virtual 2022 Toronto Cataract Course, Yeu noted that innovation is advancing in presbyopia correction.
Allergan announces positive topline Phase 3 results for presbyopia therapeuticApril 5th 2022
According to the company, the VIRGO trial evaluated the safety and efficacy of the investigational twice-daily administration of pilocarpine HCl ophthalmic solution 1.25% in adults with presbyopia. The trial met its primary efficacy endpoint, the company noted.
Visus Therapeutics kicks off Phase 3 pivotal trial for presbyopia treatmentMarch 22nd 2022
The company has dosed the first patients in a Phase 3 trial evaluating the safety and efficacy of Brimochol PF, a preservative-free topical ophthalmic solution for the treatment of presbyopia.